New Anxiety Drug Aims to 'Fine-Tune' Brain's Master Regulator

BASEL, Switzerland – May 20, 2026 – A potentially transformative new chapter in the treatment of anxiety has begun, as Swiss biotech firm Synendos Therapeutics announced the start of its Phase 2 clinical trial for a first-in-class drug aimed at Generalized Anxiety Disorder (GAD). The trial marks the first time a molecule from this new class, known as Selective Endocannabinoid Reuptake Inhibitors (SERIs), is being administered to a patient population, signaling a major step forward in neuropsychiatric medicine.

The study, conducted in collaboration with the esteemed Professor Allan Young and King’s College, London, will evaluate the company’s lead candidate, SYT-510. Following a highly successful Phase 1 trial in healthy volunteers that confirmed the drug's safety and ability to penetrate the central nervous system, this new phase will test its efficacy in those living with GAD. With preliminary data anticipated in early 2027, the trial could validate a novel therapeutic strategy that has been years in the making.

A New Mechanism for an Old Foe

At the heart of Synendos's approach is the endocannabinoid system (ECS), a complex network of cellular signals often described as the body's 'master regulator.' The ECS plays a critical role in maintaining homeostasis, or balance, across key functions including mood, stress, sleep, and appetite. While the therapeutic potential of this system has long been recognized, previous attempts to harness it have faced challenges, including the psychoactive side effects associated with direct cannabis-like activation of cannabinoid receptors.

SYT-510 represents a fundamentally different strategy. As a SERI, it doesn't directly activate receptors. Instead, it works by inhibiting the reuptake of the body’s own endocannabinoids, such as anandamide. This subtle action gently increases the concentration of these natural mood-regulating molecules in the brain, restoring their signaling capacity without overstimulating the system.

“SERIs represent a new class of endocannabinoid system modulators designed to restore healthy brain signaling by gently enhancing endogenous cannabinoid activity to unleash its full therapeutic potential without overstimulation,” said Dr. Andrea Chicca, CEO and co‑founder at Synendos. This 'fine-tuned' mechanism aims to support brain homeostasis in a precise and powerful way, potentially avoiding the drawbacks seen with earlier cannabinoid-based therapies.

This approach stands in stark contrast to existing treatments, offering a more nuanced way to rebalance brain chemistry that has been dysregulated by chronic anxiety.

Addressing a Critical Unmet Need

The need for new GAD therapies is immense. The global market for GAD treatments, valued at over $1.7 billion in 2024, is projected to climb towards $3 billion by 2034, reflecting both rising awareness and the persistent shortcomings of current options. For decades, the standard of care has relied on medications like selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines.

While helpful for many, these drugs are not a panacea. SSRIs can take weeks to become effective and come with a host of side effects that lead many patients to discontinue treatment. Benzodiazepines, though fast-acting, carry a significant risk of dependence, cognitive impairment, and are not recommended for long-term use. This leaves a large population of patients who are either undertreated or struggling with the trade-offs of their current medication.

SYT-510 aims to fill this gap by addressing the key unmet need for a treatment with sustained efficacy and better chronic tolerability. The hope is that by restoring the brain's natural regulatory system, more patients will be able to stay on treatment long-term, allowing them to regain a better quality of life without the burden of debilitating side effects.

From Lab to Clinic: The Trial in Focus

The ongoing Phase 2 trial builds on a solid foundation of preclinical and Phase 1 research. Last year's study in 60 healthy volunteers demonstrated an excellent safety profile and, crucially, provided EEG data indicating a brain effect consistent with that of established anti-anxiety medicines.

The current trial will administer a single dose of SYT-510 to unmedicated participants diagnosed with GAD. The study's crossover design will allow researchers to meticulously assess the drug's efficacy, safety, and pharmacokinetics. A key element of the trial is the collaboration with King’s College, London, which brings a powerful neuroimaging component to the research.

“At King’s, we are evaluating SYT‑510, the first‑in‑class SERI in anxiety disorders, using our established experimental medicine model, which quantifies the drug’s effects on the amygdala—a central hub of fear and anxiety processing that shows heightened activity in individuals with moderate to severe anxiety,” said Professor Allan Young, Chair of Academic Psychiatry at Imperial College London.

Beyond measuring changes in brain activity, the study will also focus on tangible, patient-centric outcomes. “In addition to characterizing its effects on the amygdala, this study will address patient‑relevant outcomes, including the impact on social avoidance—a common, disabling feature of anxiety disorders that significantly impairs social relationships and work life,” noted Dr. George Garibaldi, Chief Medical Officer at Synendos.

By combining advanced brain imaging with real-world functional measures, Synendos aims to build a comprehensive picture of SYT-510’s potential to not only reduce anxiety symptoms but also restore a patient’s ability to fully engage with their life.